New COVID-19 test to differentiate between lethal and non-lethal infections
A test for the potentially fatal COVID-19 strain of coronavirus is now available from Randox Laboratories.
The test, developed on Randox’s patented Biochip Technology, is an enhanced multiplex array that includes tests for COVID-19 and nine other respiratory viruses, which can display the same symptoms. The new enhanced Biochip allows clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.
Dr. Peter FitzGerald, Managing Director of Randox Laboratories, commented, “Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of COVID-19, and neglect to differentiate between this strain and other respiratory infections. We have developed an extended viral respiratory infection array that tests simultaneously for COVID-19 and nine other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found and empower clinicians to make fast and informed decisions.”
The test is available on the Randox Evidence Investigator with a turnaround time of five hours.
Benefits of the new Randox COVID-19 test:
• Quick turnaround times (five hours on Evidence Investigator)
• Multiplex array differentiates between mild and serious infection
• Automated and semi-automated options available
• Medium to high throughput (54 samples in five hours)
